SLS
NASDAQSELLAS Life Sciences Group Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$9.97-0.64 (-6.03%)
01:30 PM07:45 PM
News · 26 weeks190%
2026-04-192026-10-11
Mix790d
- Other4(57%)
- SEC Filings3(43%)
Latest news
25 items- PRSELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic CancerSLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology - NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinic
- PRSELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel
- SECSEC Form 10-Q filed by SELLAS Life Sciences Group Inc.10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSEC Form SCHEDULE 13G filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- INSIDERPresident and CEO Stergiou Angelos M. was granted 1,065,000 shares, increasing direct ownership by 153% to 1,759,183 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSEC Form S-8 filed by SELLAS Life Sciences Group Inc.S-8 - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences to Participate in Upcoming Investor ConferencesNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology ForumFormat: Corporate Presentation and Fireside ChatDate and Time: Tuesday, May 19, 2026, at 2:00 PM ETLocation: New York, NYWebcast Link: Click here A.G.P.'s Annual Virtual Healthcare ConferenceFormat: Fireside Chat Date: Wednesday, May
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or
- SECSEC Form 10-Q filed by SELLAS Life Sciences Group Inc.10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSEC Form S-3ASR filed by SELLAS Life Sciences Group Inc.S-3ASR - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nov
- SECSEC Form 10-K filed by SELLAS Life Sciences Group Inc.10-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR ConferenceNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r
SLS FAQ
6 questionsWhat does SELLAS Life Sciences Group Inc. do?
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage...Where does SLS stock trade?
SELLAS Life Sciences Group Inc. (SLS) is listed on NASDAQ.What sector and industry is SLS in?
SELLAS Life Sciences Group Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SLS?
SELLAS Life Sciences Group Inc. has had 1 recent analyst action on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1800.00 price target on 2021-07-21. Recent price targets cluster around $1800.00.What companies are similar to SLS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SLS side-by-side with any of them on Quantisnow.How can I track SLS on Quantisnow?
Quantisnow aggregates SELLAS Life Sciences Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLS to receive live email and push alerts on every new disclosure.